The efficacy of macrolides in the treatment of bronchiectasis colonised by Ps aeruginosa Source: Eur Respir J 2004; 24: Suppl. 48, 638s Year: 2004
Antibiotic efficacy varies based on the infection model and treatment regimen for Pseudomonas aeruginosa Source: Eur Respir J, 55 (3) 1802456; 10.1183/13993003.02456-2018 Year: 2020
Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005
Eradication of Pseudomonas aeruginosa in cystic fibrosis patients Source: Eur Respir J 2006; 27: 653 Year: 2006
Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014
Inhaled phage therapy for the treatment of acute Pseudomonas aeruginosa lung infections Source: International Congress 2018 – Mechanisms of respiratory infection Year: 2018
Pseudomonas aeruginosa in patients with cystic fibrosis - a comparison of early eradication and conventional therapySource: Eur Respir J 2004; 24: Suppl. 48, 385s Year: 2004
Eradication of Pseudomonas aeruginosa in cystic fibrosis Source: Eur Respir J 2006; 27: 438-439 Year: 2006
Novel Pseudomonas aeruginosa scoring system to guide empiric anti-pseudomonal therapy in COPD patients with community-acquired pneumònia Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020
Pseudomonas aeruginosa eradication therapy on Cystic Fibrosis- Guideline and clinical routine Source: International Congress 2018 – Cystic fibrosis in adults: current research Year: 2018
Eradication treatment in Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017
Azithromycin therapy and pseudomonas aeruginosa isolation in a non-cystic fibrosis bronchiectasis cohort Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives Year: 2015
The efficacy of early eradication therapy in prevention of chronic pseudomonas aeruginosa infection in cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 486s Year: 2006
Omics-based tracking of Pseudomonas aeruginosa persistence in “eradicated” cystic fibrosis patients Source: Eur Respir J, 57 (4) 2000512; 10.1183/13993003.00512-2020 Year: 2021
Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis}, Source: Eur Respir J 2012; 40: 1014-1023 Year: 2012
The clinical impact of nebulised antibiotics in adults with bronchiectasis and chronic pseudomonas aeruginosa Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020
Pulmonary infections with pseudomonas aeruginosa Source: Eur Respir J 2004; 24: Suppl. 48, 642s Year: 2004
Epidemiological-molecular study of colonization by pseudomonas aeruginosa in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 379s Year: 2002
Immunomodulatory properties of macrolide antibiotics in the treatment of bronchial sepsis involving P. aeruginosa Source: Eur Respir J 2004; 24: Suppl. 48, 639s Year: 2004